Focus on natural origin and oncology APIs, setting up R&D and production platform for new salt and crystal form, deep cooperation with clients for IND, NDA, ANDA, 505b(2) or P-IV challenge.
Explore the potential of macromolecular APIs, setting up R&D and production platform for Glycans and polypeptide.
Specialized in XDC drugs field, committed to platform building for the innovative research and production on payload and Best-Link.
Global registration platform, professional team, and international cGMP system.
API CDMO service with global registration.
Strategy: FDF + APIs.
Tel: +86-28-17360040767
Website: www.xielipharm.com.cn、www.elixir-pharm.com
more >
Year of Establishment:
2021
Total Number of Staff:
10-50
Main Competitive Advantages:
Brand Name,International Approvals/Standards,Experienced R&D Staff,Small Orders Accepted,Quality Service
Other Competitive Advantages:
R&D Team
(1)Stable R&D team with over 10 years of experience, more than 20 successful R&D projects.
(2)Synthesis Lab with GRLP standard.
(3)Analysis Lab in accordance with GMP conditions.
(4)In collaboration with well-known universities, focus on new salt, new crystal form and novel technologies, such as synthetic biology and continuous-flow synthetic.
Patents and Copyrights:
Business Type:
Agent,Distributor,Trading Company,Retailer,Service Provider,Manufacturer
R&D capacity:
Own Brand
Annual Turnover(USD):
Main Sales Markets:
North America,Central/South America,Western Europe,Eastern Europe,Asia,Middle East
Advantage Description: